Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.

Ulrike A NitzOleg Gluz Sherko Kuemmel Matthias ChristgenMichael BraunBahriye Aktaş Kerstin Lüdtke-Heckenkamp Helmut ForstbauerEva-Maria GrischkeClaudia SchumacherMaren DarsowKatja KraussBenno NudingMarc ThillJochem PotenbergChristoph UleerMathias WarmHans Holger Fischer Wolfram Malter Michael HauptmannRonald E KatesMonika GräserRachel WürstleinSteven ShakFrederick L BaehnerHans H KreipeNadia Harbeck

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

WSG-ADAPT-HR+/HER2- demonstrates that guiding systemic treatment by both RS and ET response is feasible in clinical routine and spares CT in pre- and postmenopausal patients with ≤ 3 involved lymph nodes.

Keyphrases

gene expression
lymph node
early breast cancer
dna methylation
computed tomography
stem cells
magnetic resonance imaging
clinical practice
bone mineral density
contrast enhanced
image quality
mesenchymal stem cells
dual energy
body composition